

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

DATE OF MEETING OF THE BOARD OF DIRECTORS

The board of directors (the “**Board**”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”, and its subsidiaries, the “**Group**”) announces that a meeting of the Board will be held on Friday, 28 August 2026 for the purposes of considering and approving the interim results of the Group for the six months ended 30 June 2026 for publication and transacting any other business, including the recommendation on the payment of an interim dividend, if any.

By Order of the Board

Fujian Haixi Pharmaceuticals Co., Ltd.

Dr. Kang Xinshan

Executive Director, Chairman and General Manager

Hong Kong, 12 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming, Mr. Li Junqing and Mr. Chen Tingze as executive Directors; (ii) Mr. Xu Dong as non-executive Director; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.